National Resilience, Inc.: Influenza, Human trials

The registry lists 25 Influenza, Human studies with National Resilience, Inc. as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 10Phase 2 11Phase 3 13No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)CompletedNCT01773928Phase 3Results posted
• Reverse Genetic H9N2 Influenza Vaccine Study in AdultsCompletedNCT01320696Phase 1/2Results posted
• Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza InfectionCompletedNCT00800605Phase 3Results posted
• Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and OlderCompletedNCT00782431Phase 3Results posted
• Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)CompletedNCT00566345Phase 3Results posted
• Japanese Pediatric H5N1 Vaccine StudyCompletedNCT01911754Phase 3
• H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and OlderCompletedNCT01774032Phase 3
• Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young AdultsCompletedNCT01258062Phase 1
• Yearly Strain Variation Study, 2010/2011CompletedNCT01157702Phase 3
• Adult Safety Study of 2009/2010 Seasonal Influenza VaccineCompletedNCT01063088Phase 3
• A/H1N1 Immunogenicity and Safety in Infants, Children and AdolescentsCompletedNCT00976469Phase 1/2
• A/H1N1 Immunogenicity and Safety in AdultsCompletedNCT00959465Phase 1/2
• Observational Study to Assess Safety of H1N1 Pandemic Influenza VaccineCompletedNCT00950456
• Yearly Strain Variation Study, 2009/2010CompletedNCT00943657Phase 3
• Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in AdultsCompletedNCT00895544Phase 1/2
• Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)CompletedNCT00783926Phase 1
• Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsCompletedNCT00711295Phase 3
• Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)CompletedNCT00530660Phase 2
• Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00517517Phase 1/2
• Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00462215Phase 3
• Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)CompletedNCT00424086Phase 1/2
• Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00349141Phase 1/2
• Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00289510Phase 1/2
• Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004CompletedNCT00161837Phase 2/3
• Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005CompletedNCT00161811Phase 2/3